Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
6kftqW7ve5LJ8V7g
Listen
Français